1. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (10831)
  2. Meeting Abstract (9435)
  3. Review (542)
  4. Book Section (410)
  5. Editorial (324)
  6. Guidelines (154)
  7. Correspondence (115)
  8. Conference Paper (106)
  9. Research Letter (60)
  10. Miscellaneous (53)
  11. Book Whole (27)
Groups
  1. Solid Tumor Oncology Division (22057)
  2. Department of Medicine (22035)
  3. GSK Faculty (5880)
  4. Genitourinary Oncology Service (5608)
  5. Survivorship Research (5184)
  6. Gastrointestinal Oncology Service (4640)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (869)
  6. Leonard Saltz (790)

More People

Years
  1. 2025 (445)
  2. 2024 (1382)
  3. 2023 (1380)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1535)

More Years

Publications
  1. Journal of Clinical Oncology (5227)
  2. Annals of Oncology (1294)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (768)
  5. Journal of Thoracic Oncology (530)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5507)
  2. Elsevier Inc. (2651)
  3. American Association for Cancer Research (2316)
  4. Oxford University Press (1810)
  5. Nature Publishing Group (1026)
  6. Springer (975)

More Publishers

Results (22057)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Multi-omic characterization of lung tumors identify AKT and EZH2 as potential therapeutic targets in adenocarcinoma-to-squamous transdifferentiation
    Meeting Abstract

    Quintanal-Villalonga, Á.; Taniguchi, H.; Zhan, Y. A.; Hasan, M. M.; Chavan, S. S.; Uddin, F.; Allaj, V.; Manoj, P.; Shah, N.; Ciampricotti, M.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • XPO1 inhibition strongly sensitizes to first-line and second-line therapy in small cell lung cancer
    Meeting Abstract

    Quintanal‐Villalonga, Á.; Taniguchi, H.; Hao, Y.; Chow, A.; Zhan, Y. A.; Uddin, F.; Allaj, V.; Manoj, P.; Shah, N.; Chan, J. M.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Primary data from DESTINY-Lung01: A phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Li, B. T.; Smit, E. F. F.; Goto, Y.; Nakagawa, K.; Udagawa, H.; Mazieres, J.; Nagasaka, M.; Bazhenova, L.; Saltos, A. N.; Felip, E.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 study
    Meeting Abstract

    Janjigian, Y. Y.; Ajani, J. A.; Moehler, M.; Garrido, M.; Gallardo, C.; Shen, L.; Yamaguchi, K.; Wyrwicz, L.; Skoczylas, T.; Bragagnoli, A.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen
    Meeting Abstract

    van Cutsem, E.; Di Bartolomeo, M.; Smyth, E.; Chau, I.; Park, H.; Siena, S.; Lonardi, S.; Wainberg, Z. A.; Ajani, J. A.; Chao, J.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Association of homologous recombination deficiency (HRD) with clinical outcomes in a phase III study of olaparib or cediranib and olaparib compared to platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer (PSOC): Biomarker analyses from NRG-GY004
    Meeting Abstract

    Swisher, E.; Miller, A.; Kohn, E.; Brady, M.; Radke, M.; Pennil, C.; Khasnavis, N.; Buscema, J.; Tew, W.; Muller, C.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation
    Meeting Abstract

    Weiss, J.; Yaeger, R. D.; Johnson, M. L.; Spira, A.; Klempner, S. J.; Barve, M. A.; Christensen, J. G.; Chi, A.; Der-Torossian, H.; Velastegui, K.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Early reduction in ctDNA, regardless of best RECIST response, is associated with overall survival (OS) on tebentafusp in previously treated metastatic uveal melanoma (mUM) patients
    Meeting Abstract

    Shoushtari, A. N.; Collins, L.; Espinosa, E.; Sethi, H.; Stanhope, S.; Abdullah, S.; Ikeguchi, A.; Ranade, K.; Hamid, O.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • The gamma secretase inhibitor AL101 combined with other drugs for dual targeting of Notch dysregulated tumors
    Meeting Abstract

    Ferrarotto, R.; Rauch, R.; Leibovich, T.; Shitrit, A.; Solomon, O.; Herz, E.; Walker, R. M.; Ho, A. L.; Kaye, J.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Safety and preliminary efficacy of vimseltinib in tenosynovial giant cell tumor (TGCT)
    Meeting Abstract

    Gelderblom, H.; Abdul Razak, A. R.; Sánchez-Gastaldo, A.; Rutkowski, P.; Wilky, B.; Wagner, A.; van de Sande, M.; Michenzie, M.; Vallee, M.; Sharma, M.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save